The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately Day 211
Maximum Observed Plasma Concentration (Cmax) of ABBV-1451
Timeframe: Up to Approximately Day 211
Time to Cmax (Tmax) of ABBV-1451
Timeframe: Up to Approximately Day 211
Terminal Phase Elimination Rate Constant (β) of ABBV-1451
Timeframe: Up to Approximately Day 211
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1451
Timeframe: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-1451
Timeframe: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-1451
Timeframe: Up to Approximately Day 211